DprE1-IN-1 is a potent and orally active DprE1 inhibitor with good hepatocyte stability, low cytotoxicity, and low hERG channel inhibition; it exhibits effective activity against both drug-sensitive and clinically isolated drug-resistant Mycobacterium tuberculosis strains (MICs < 0.1 μg/mL) and demonstrates strong intracellular anti-mycobacterial activity in macrophages, reducing bacterial load by 1.29 log10 CFU.